Clinical Trials Logo

Clinical Trial Summary

This is a pilot phase II study to evaluate the safety and efficacy of AND017 in NDD-CKD patients

Clinical Trial Description

This is a pilot phase 2, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-ranging, safety and efficacy study of oral AND017 to treat anemia in non-dialysis-dependent chronic kidney disease patients. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05035641
Study type Interventional
Source Kind Pharmaceuticals LLC
Contact Qi Zhu
Phone 617-780-8445
Email [email protected]
Status Recruiting
Phase Phase 2
Start date August 16, 2021
Completion date October 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04925661 - HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia Phase 1
Active, not recruiting NCT03388385 - Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD Phase 4
Completed NCT02299661 - Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease Phase 1
Not yet recruiting NCT02708914 - Study to Compare the Safety and Efficacy of UB-851 and Eprex® Phase 3
Completed NCT02041208 - Variability of Hemoglobin Levels After Kidney Transplantation N/A
Not yet recruiting NCT04775615 - Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects. Phase 1
Completed NCT00298441 - Efficacy of Intravenous Iron Administration in Hemodialysis Patients Phase 4
Recruiting NCT04408820 - Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Dialysis-dependent Patients With Renal Anemia
Completed NCT01543477 - Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia
Recruiting NCT04454879 - Different Doses of Roxadustat Treatment for Anemia in Peritoneal Dialysis Patients Phase 4
Recruiting NCT04360902 - Assessment of an Anemia Model Predictive Controller for Anemia Management in Hemodialysis Patients N/A
Not yet recruiting NCT03480178 - Renal Anemia Refractory to Erythropoietin
Completed NCT01306409 - Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA) Phase 4
Completed NCT00322413 - Comparison of Epoetin Alfa and Epoetin Omega in Anemic Dialysis Patients:Results of Efficacy Trial Phase 3
Recruiting NCT02947438 - Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study) Phase 3
Completed NCT00456053 - A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin Phase 2
Recruiting NCT04899661 - A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia
Completed NCT02136563 - Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents
Completed NCT04227158 - The Association Between the Distributions MCH and RBC, and Mortality in Hemodialysis Patients